Onconetix, Inc. (ONCO) - Dilution Analysis

8-K filing: Stock split 1-for-10 | Outstanding: 11,464,572 → 1,140,000

10-Q filing | 11.5M shares outstanding

S-1/A filing: Form of Registration Rights Agreement relating to the resale of the shares of Common Stock underlying the Series C Preferred Stock and Warrants

10-K filing | 3.6M shares outstanding

10-Q filing | 1.4M shares outstanding

S-1 filing: This prospectus relates to the resale by Selling Stockholders of 22,071,891 shares of common stock of Onconetix, Inc.

S-1 filing: This is an S-1 filing for Onconetix, Inc. regarding the offer and sale of up to 5,100,000 shares of common stock by Keystone Capital Partners, LLC pursuant to a Common Stock ELOC Purchase Agreement.

8-K filing: Onconetix, Inc. entered into a securities purchase agreement to sell Series D convertible preferred stock and warrants for an aggregate purchase price of approximately $12.9 million and settled Veru Notes with cash, Series D Preferred Stock, and Warrants. ($19.2M proceeds)

10-Q filing | 1.5M shares outstanding

8-K filing: Stock split 1-for-85 | Outstanding: 44,358,422 → 521,863

10-Q filing | 44.4M shares outstanding

10-K filing | 44.4M shares outstanding

S-1/A filing: This S-1/A filing relates to the offer and sale of up to 50,000,000 shares of common stock by Keystone Capital Partners, LLC, pursuant to an equity line of credit agreement, and to a warrant inducement.

S-1 filing: Onconetix, Inc. is offering up to 50,000,000 shares of common stock through an equity line of credit with Keystone Capital Partners, LLC, and also new preferred investment options to purchase up to an aggregate of 559,397 shares of the Company's common stock.

10-Q filing | 8.3M shares outstanding

S-1/A filing: Onconetix, Inc. is offering 6,250,000 shares of common stock through Keystone Capital Partners, LLC, pursuant to an equity line of credit. Additionally, they closed a warrant inducement offering on July 12, 2024.

8-K filing: Onconetix, Inc. amended its forbearance agreement with Veru Inc., modifying payment terms related to a prior asset purchase agreement and increasing the percentage of net proceeds from future financings to be paid to Veru.

S-1/A filing: This S-1/A filing, dated November 12, 2024, relates to the offer and sale of up to 6,250,000 shares of common stock by Keystone Capital Partners, LLC pursuant to a Common Stock ELOC Purchase Agreement, and also discusses a warrant inducement offer.

S-1/A filing: S-1/A filing on 2024-11-12 regarding 13,054 shares of common stock issuable upon exercise of common stock preferred investment options.

S-1 filing: Onconetix, Inc. is offering 6,250,000 shares of common stock through an equity line of credit with Keystone Capital Partners, LLC and also relates to warrant inducement of 559,397 shares.

S-1 filing: This S-1 filing registers 10,586,556 shares of common stock for resale by selling stockholders.

8-K filing: Onconetix, Inc. entered into a securities purchase agreement with PIPE Investors for the sale of Series C convertible preferred stock and warrants for aggregate cash proceeds of $2.0 million, and also entered into a Common Stock Purchase Agreement with an ELOC Purchaser for up to $25 million of newly issued Common Stock. ($2.0M proceeds)

8-K filing: Stock split 1-for-40 | Outstanding: 29,790,119 → 755,031

8-K filing | Stock split 1-for-40 | Outstanding: 29,790,119 → 744,752 | Transactions: Issuance 142749 Common stock to Veru Inc.; Issuance 6741820 Common stock to certain stockholders of Proteomedix AG; Issuance 513424 Common stock to Altos Venture AG; Exercise 154027 Warrant to Altos Venture AG

8-K filing: Onconetix, Inc. is holding an annual meeting of stockholders on September 5, 2024, to vote on the issuance of common stock upon conversion of Series B Preferred Stock, a private placement financing of units, and the assumption and conversion of outstanding stock options of Proteomedix AG. ($5.0M proceeds)

10-Q filing | 29.8M shares outstanding

8-K filing: On July 15, 2024, Onconetix, Inc. consummated the transactions contemplated by the Inducement Letter, with certain holders exercising their existing preferred investment options to purchase an aggregate of 7,458,642 shares of the Company's common stock at a reduced exercise price of $0.15 per share, in exchange for the Company's agreement to issue new PIOs to purchase up to 22,375,926 shares of the Company's common stock.

8-K filing: Onconetix, Inc. entered into an inducement letter agreement with certain holders of existing preferred investment options (PIOs) to purchase shares of the Company's common stock. Holders agreed to exercise their Existing PIOs to purchase 7,458,642 shares of the Company's common stock at a reduced exercise price of $0.15 per share, in consideration for the Company's agreement to issue new PIOs to purchase up to an aggregate of 22,375,926 shares. ($1.12M proceeds)

S-1/A filing: This prospectus relates to the resale by Selling Stockholders of 7,828,812 shares of common stock of Onconetix, Inc.

S-1/A filing: This prospectus relates to the resale by Selling Stockholders of 7,828,812 shares of common stock of Onconetix, Inc.

10-Q filing | 22.1M shares outstanding

S-1/A filing: This S-1/A filing relates to the resale of 7,828,812 shares of common stock by selling stockholders of Onconetix, Inc.

8-K filing: Onconetix, Inc. entered into a Forbearance Agreement with Veru Inc. where Veru will forbear from exercising its rights and remedies under the April Veru Note until March 31, 2025, with interest accruing at 10% per annum, and the Debenture was amended to extend the maturity date to the earlier of (i) the closing under the Subscription Agreement and (ii) October 31, 2024.

10-K filing | 22.3M shares outstanding

S-1 filing: This S-1 filing relates to the resale of 5,121,601 shares of common stock by selling stockholders.

8-K filing: Onconetix acquired Proteomedix by issuing 4,083,779 shares of common stock and 2,692,633 shares of Series B Convertible Preferred Stock convertible into 269,263,300 shares of common stock, and also changed its name from Blue Water Biotech, Inc. to Onconetix, Inc.

10-Q filing | 17.5M shares outstanding

10-Q filing | 18.0M shares outstanding

8-K filing: Blue Water Biotech consummated a transaction where a holder exercised existing preferred investment options to purchase 2,486,214 shares of common stock at $1.09 per share, in exchange for the company issuing new preferred investment options to purchase up to 4,972,428 shares. ($2.71M proceeds)

8-K filing: Blue Water Biotech, Inc. entered into an inducement letter with a holder to exercise existing preferred investment options for 2,486,214 shares of common stock at $1.09 per share, in exchange for new preferred investment options to purchase up to 4,972,428 shares. ($2.71M proceeds)

8-K filing: Blue Water Biotech, Inc. will issue 1.0 million shares of its common stock as part of an asset purchase agreement with WraSer, LLC and Xspire Pharma, LLC. ($8.5M proceeds)

10-Q filing | 15.9M shares outstanding

POS AM filing: This is a POS AM filing for common stock. The filing indicates that there are 15,924,070 shares of common stock outstanding as of April 15, 2023. It also mentions warrants exercisable for 5,264,274 shares.

S-3 filing: This is an S-3 filing for a shelf offering of common stock, preferred stock, purchase contracts, warrants, subscription rights, depositary shares, and debt securities.

10-K filing | 15.9M shares outstanding

10-Q filing | 14.3M shares outstanding

8-K filing: The Company settled with Boustead Securities, waiving right of first refusal and standstill provisions in exchange for $1,050,000 and the issuance of 93,466 shares of restricted common stock in exchange for the cancellation of a representative warrant.

S-1 filing: This S-1 filing registers Placement Shares and Warrant Shares on behalf of Selling Stockholders.

10-Q filing | 13.6M shares outstanding

8-K filing: Blue Water Vaccines Inc. closed a private placement, issuing 1,350,000 shares of common stock, pre-funded warrants to purchase 2,333,280 shares, and preferred investment options to purchase up to 4,972,428 shares, raising approximately $10.0 million in gross proceeds. ($10.0M proceeds)

S-1/A filing: This S-1/A filing registers the Placement Shares and Warrant Shares on behalf of the Selling Stockholders, to be offered and sold by them from time to time.

10-Q filing | 11.6M shares outstanding

S-1 filing: This S-1 filing registers placement shares and warrant shares on behalf of selling stockholders, who may sell these shares from time to time. The company will not receive any proceeds from the sale of common stock by the selling stockholders.

8-K filing: Blue Water Vaccines Inc. consummated a private placement, issuing 590,406 shares of common stock, pre-funded warrants to purchase 590,406 shares, and preferred investment options to purchase up to 1,180,812 shares, for gross proceeds of approximately $8.0 million. ($4.0M proceeds)

8-K filing: Blue Water Vaccines Inc. completed a public offering of 2,222,222 shares of common stock at $9.00 per share, resulting in net proceeds of approximately $17.8 million, and converted all outstanding series seed preferred stock into 5,626,365 shares of common stock.

S-1/A filing: This S-1/A filing relates to a common stock offering managed by Boustead Securities, LLC. The prospectus includes information for investors outside the United States and mentions trademark usage.

S-1/A filing: This is an S-1/A filing for an offering managed by Maxim Group LLC, including common stock and warrants.

S-1/A filing: This S-1/A filing registers common stock and warrants with Maxim Group LLC as the sole book-running manager.

S-1/A filing: This is an S-1/A filing for an offering managed by Maxim Group LLC. The filing includes common stock and warrants. The registration statement is being amended to delay its effective date.

S-1/A filing: This is an S-1/A filing for a common stock offering with warrants, managed by Maxim Group LLC.

S-1/A filing: This is an S-1/A filing for a common stock offering managed by Maxim Group LLC. The filing includes warrants exercisable at 115% of the common stock's public offering price.

S-1 filing: S-1 filing for common stock offering managed by Maxim Group LLC, including potential over-allotment shares and representative's warrants. Registration fee is paid, and the effective date may be delayed.